Roche announced that the European Commission (EC) approved Vabysmo (faricimab) for the treatment of neovascular or wet age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME). These retinal conditions are two of the leading causes of vision loss worldwide, affecting more than 40 million people.
- Read more about European Commission approves Roches Vabysmo, antibody for the eye
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/european-commission-approves-roches-vabysmo-antibody-for-the-eye
No comments:
Post a Comment